Gb Sciences, Inc. (OTCQB:GBLX)

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 18 U.S. and 49 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human trial.

Upcoming Events

Alcor Drug Discovery Platform Summit May 12, 2022, Virtual
Neuro Forum Summit 2022 May 23, 2022, Virtual
The 5th Cannabinoid Derived Pharmaceuticals Summit Sept 7, 2022, Boston
Canna Pharma Conference Oct 12-13, 2022, San Diego

Most Recent Investor Presentation

Gb Sciences’ Drug Development Programs

Letter to Shareholder's

GBLX Stock Price

The GBLX stock price will be updated periodically, but there may be a lag with respect to real-time stock quotes

SEC Filings for Gb Sciences, Inc.

Latest News from Gb Sciences

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences’ COVID-19 Related Anti-Inflammatory Therapies

Gb Sciences Issues Shareholder Letter 

Media Contact

Alexis Quintal

connect@alexisrose.co